Skip to content
  • Kategorier
  • Seneste
  • Etiketter
  • Populære
  • Verden
  • Bruger
  • Grupper
Temaer
  • Light
  • Brite
  • Cerulean
  • Cosmo
  • Flatly
  • Journal
  • Litera
  • Lumen
  • Lux
  • Materia
  • Minty
  • Morph
  • Pulse
  • Sandstone
  • Simplex
  • Sketchy
  • Spacelab
  • United
  • Yeti
  • Zephyr
  • Dark
  • Cyborg
  • Darkly
  • Quartz
  • Slate
  • Solar
  • Superhero
  • Vapor

  • Default (No Skin)
  • No Skin
Kollaps
  1. Debatforum
  2. Kategorier
  3. Genmab
  4. Genmab — Juli 2024

Genmab — Juli 2024

Planlagt Fastgjort Låst Flyttet Genmab
568 Indlæg 1 Posters 0 Visninger
  • Ældste til nyeste
  • Nyeste til ældste
  • Most Votes
Svar
  • Svar som emne
Login for at svare
Denne tråd er blevet slettet. Kun brugere med emne behandlings privilegier kan se den.
  • P Offline
    P Offline
    peter12
    wrote on sidst redigeret af
    #129

    Er der nogen der ved om Genmab evt kan forny deres CD38 patent https://patents.google.com/patent/JP2024075737A/en

    1 Reply Last reply
    0
    • S Offline
      S Offline
      Sukkeralf
      wrote on sidst redigeret af
      #130

      Det er på HexCD38

      1 Reply Last reply
      0
      • P Offline
        P Offline
        peter12
        wrote on sidst redigeret af
        #131

        Ok det kan være lidt svært at se 😉

        1 Reply Last reply
        0
        • T Offline
          T Offline
          transalp
          wrote on sidst redigeret af
          #132

          Go morgen.. 🙂

          1 Reply Last reply
          0
          • Helge_LarsenPI-redaktørH Offline
            Helge_LarsenPI-redaktørH Offline
            Helge_LarsenPI-redaktør
            wrote on sidst redigeret af
            #133

            Godmorgen 🙂

            1 Reply Last reply
            0
            • L Offline
              L Offline
              LP90
              wrote on sidst redigeret af
              #134

              Godmorgen 🙂

              1 Reply Last reply
              0
              • B Offline
                B Offline
                bibob
                wrote on sidst redigeret af
                #135

                God morgen. 🙂

                1 Reply Last reply
                0
                • L Offline
                  L Offline
                  lahn1
                  wrote on sidst redigeret af
                  #136

                  Godmorgen 🙂

                  1 Reply Last reply
                  0
                  • V Offline
                    V Offline
                    Vitus
                    wrote on sidst redigeret af
                    #137

                    StockBull….har du ikke kludder i
                    månedernes rækkefølge….

                    1 Reply Last reply
                    0
                    • E Offline
                      E Offline
                      E_L
                      wrote on sidst redigeret af
                      #138

                      Ben Derman
                      @bdermanmd
                      Let’s talk about freedom…from spending as much time in clinic!

                      We piloted discontinuation of premeds for daratumumab starting cycle 2 (we kept dex) and had no adverse events! https://x.com/bdermanmd/status/1808701446549807569

                      1 Reply Last reply
                      0
                      • E Offline
                        E Offline
                        E_L
                        wrote on sidst redigeret af
                        #139

                        We shortened each visit by 1 hour (= $740) amounting to 194 hours and $140K saved in just 6 months.

                        At scale, this has huge potential implications - $21,900 saved per patient adhering to ANDROMEDA and $27K per patient per GRIFFIN (similar for PERSEUS)!

                        1 Reply Last reply
                        0
                        • E Offline
                          E Offline
                          E_L
                          wrote on sidst redigeret af
                          #140

                          The New England Journal of Medicine - Tisotumab Vedotin as Second- or Third-Line Therapy for Recurrent Cervical Cancer https://www.nejm.org/doi/full/10.1056/NEJMoa2313811

                          1 Reply Last reply
                          0
                          • E Offline
                            E Offline
                            E_L
                            wrote on sidst redigeret af
                            #141

                            Health Canada Authorizes RYBREVANT® (amivantamab) in Combination with Carboplatin and Pemetrexed https://finance.yahoo.com/news/health-canada-authorizes-rybrevant-amivantamab-120000634.html

                            1 Reply Last reply
                            0
                            • E Offline
                              E Offline
                              E_L
                              wrote on sidst redigeret af
                              #142

                              PERSEUS Data Support Daratumumab as New Standard of Care for Myeloma https://bloodcancerstoday.com/post/perseus-data-support-daratumumab-as-new-standard-of-care-for-myeloma

                              1 Reply Last reply
                              0
                              • L Offline
                                L Offline
                                lahn1
                                wrote on sidst redigeret af
                                #143

                                Iflg Bloomberg overgåes væksten i Gmab de næste 5 år (17,5%) kun af LLY. NVO (17,2%) blandt alle de 15 største pharma/biotech. En vækst historie som markedet tilsyneladende ikke tror på, da den skal drives af Gen1046 og Epco. HexaCD38 fylder ingenting de næste 5år.

                                1 Reply Last reply
                                0
                                • L Offline
                                  L Offline
                                  lahn1
                                  wrote on sidst redigeret af
                                  #144

                                  Uden de store armbevægelser er 2024 det sidste år DARA står for størstedelen af væksten. Herefter er det de NYE produkter der skaber vækst.

                                  1 Reply Last reply
                                  0
                                  • SolsenS Offline
                                    SolsenS Offline
                                    Solsen
                                    wrote on sidst redigeret af
                                    #145

                                    LLYs aktiekursudvikling er helt vild og prissætningen ditto.

                                    1 Reply Last reply
                                    0
                                    • P Offline
                                      P Offline
                                      ProinvestorNEWS
                                      wrote on sidst redigeret af
                                      #146

                                      Forventninger til C25 halvårsregnskaber https://proinvestor.com/boards/121235

                                      1 Reply Last reply
                                      0
                                      • SolsenS Offline
                                        SolsenS Offline
                                        Solsen
                                        wrote on sidst redigeret af
                                        #147

                                        LLY fra X https://x.com/financelancelot/status/1808207982452208060?s=61&t=JauvgjicW74kU8sNN3xEFA

                                        1 Reply Last reply
                                        0
                                        • SolsenS Offline
                                          SolsenS Offline
                                          Solsen
                                          wrote on sidst redigeret af
                                          #148

                                          Jeg vil følge Carvykti og Epco tæt de kommende kvartalsregnskaber. Mon ikke andre Genmab interesserede gær det samme 🙂

                                          1 Reply Last reply
                                          0

                                          Hello! It looks like you're interested in this conversation, but you don't have an account yet.

                                          Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.

                                          With your input, this post could be even better 💗

                                          Tilmeld Log ind
                                          Svar
                                          • Svar som emne
                                          Login for at svare
                                          • Ældste til nyeste
                                          • Nyeste til ældste
                                          • Most Votes


                                          • Log ind

                                          • Har du ikke en konto? Tilmeld

                                          • Login or register to search.
                                          Powered by NodeBB Contributors
                                          • First post
                                            Last post
                                          0
                                          • Kategorier
                                          • Seneste
                                          • Etiketter
                                          • Populære
                                          • Verden
                                          • Bruger
                                          • Grupper